A New Tool for Understanding Type 1 Diabetes: Safer Lab Models of Beta Cell Damage

Type 1 diabetes develops when the immune system destroys insulin-producing beta cells in the pancreas. To understand how this happens and test potential treatments, researchers need laboratory models that mimic beta cell damage.

For decades, scientists have used chemicals like streptozotocin and alloxan to destroy beta cells in animal studies. While these chemicals work, they have significant drawbacks: they don't always work reliably, they can damage other organs besides the pancreas, and they carry cancer risk. Scientists have been searching for better alternatives.

A team of researchers designed a new molecule called ROXendin668 that works differently. The molecule has two key parts: one that targets beta cells specifically, and another that generates reactive oxygen when exposed to red light.

ROXendin668 uses GLP-1 receptor signaling—a natural pathway in beta cells—to direct the molecule precisely where it needs to go. Once it reaches beta cells, red light activates the molecule to generate singlet oxygen, a reactive substance that damages the cells in a controlled way.

In laboratory tests, ROXendin668 successfully damaged beta cells when exposed to red light. The molecule worked on both cultured beta cells (MIN6 cells) and primary beta cells taken from animal pancreases. When delivered systemically to living animals and then activated with light, it produced localized beta cell stress in the pancreas.

The key advantage: researchers can control exactly when and where the damage occurs by turning the light on and off. This precision could lead to more accurate models of how beta cells are destroyed in Type 1 diabetes.

This new tool does not treat or prevent Type 1 diabetes itself. Instead, it provides scientists with a safer, more specific way to study the disease in the laboratory. Better research models can help scientists understand the mechanisms behind beta cell destruction and test new therapies more effectively.

By replacing older, more toxic chemical methods with ROXendin668, researchers may be able to conduct studies with fewer side effects and greater accuracy—potentially accelerating the discovery of new approaches to managing Type 1 diabetes.

Source: Angewandte Chemie (International ed. in English). Evidence type: PubMed indexed literature. Type1Cure is an information and intelligence hub, not a medical advice service. This article summarizes published research and does not provide diagnosis, treatment, or personal medical guidance. Always talk to your own care team before changing anything about your Type 1 diabetes management.